Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci.
Oropharyngeal samples from 60 hospitalized patients (30 fluoroquinolone [FQ]-treated and 30 non-FQ-treated patients) and 30 untreated nonhospitalized healthy control subjects yielded 20 isolates of viridans group streptococci with reduced susceptibility to FQ, mostly from the hospitalized patients. An efflux phenotype was commonly encountered, expressed either alone or with topoisomerase mutations. Interspecies transfer of the efflux phenotype was demonstrated via transformation of Streptococcus pneumoniae R6 with DNA from S. mitis and S. oralis.
Guerin
F
F
Service de Microbiologie, Hôpital Broussais, 75674 Paris Cedex 14, France.
Varon
E
E
Hoï
A B
AB
Gutmann
L
L
Podglajen
I
I
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001693:Biological Transport, Active; D004264:DNA Topoisomerases, Type I / Q000235:genetics; D004352:Drug Resistance, Microbial / Q000235:genetics / Q000502:physiology; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D009154:Mutation; D009960:Oropharynx / Q000382:microbiology*; D013291:Streptococcus / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism; D014169:Transformation, Bacterial
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D004264:DNA Topoisomerases, Type I